Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 9/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 11/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2505966 | 0.88 | S1PR1 (0.56) | S1PR1S1PR5S1PR3 | |
| SCHEMBL3340210 | 0.85 | S1PR1 (0.56) | S1PR1S1PR5S1PR3 | |
| SCHEMBL13303754 | 0.83 | S1PR1 (0.47) | S1PR1S1PR5S1PR3 | |
| SCHEMBL3341034 | 0.80 | NPC1 (0.44) | S1PR1S1PR3 | |
| SCHEMBL3340459 | 0.79 | S1PR1 (0.46) | S1PR1S1PR5S1PR3 | |
| SCHEMBL3340509 | 0.78 | S1PR1 (0.54) | S1PR1S1PR5S1PR3 | |
| SCHEMBL3339391 | 0.77 | S1PR1 (0.46) | S1PR1S1PR5S1PR3 | |
| SCHEMBL3339957 | 0.77 | RARA (0.39) | — | |
| SCHEMBL3340546 | 0.76 | S1PR1 (0.41) | S1PR1S1PR5S1PR3 | |
| SCHEMBL3340664 | 0.75 | S1PR1 (0.36) | S1PR1S1PR5S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885S1PR5 2/4885S1PR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.